secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001140361-26-018716
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 2.01, 5.03, 1.01, 3.02, 3.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics completes $300M all-stock acquisition of Cullgen; appoints Ying Luo as CEO
--------------------------------------------------------------------------------

- All-stock deal valued at ~$300M closed; Cullgen becomes wholly owned subsidiary.
- Ying Luo appointed CEO and President; Ping Zhang remains Chairman.
- Combined company has commercial ETUARY® in China for lung fibrosis and late-stage pipeline including F351 for liver fibrosis.
- Cullgen contributes targeted protein degrader (TPD) and degrader-antibody conjugate (DAC) pipeline.
- Company will hold stockholder meeting June 10, 2026 for approval of conversion of Series B Preferred to common.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/0001140361-26-018716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126018716/ef20072211_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-018716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer